Multiplexed assay maps function of more than 10,000 GBA1 variants relevant to Gaucher and Parkinson's disease

A preprint presents a near-comprehensive functional atlas of GBA1 single-amino-acid substitutions, offering a potential resource for interpreting variants of uncertain significance in Gaucher disease and Parkinson's disease research.

Published · AI-drafted summary based on 1 public source
Illustration for generic story
Illustrative image — not from the source article.
Share

A preprint deposited on bioRxiv on 17 November 2026 reports a multiplexed assay of variant effect (MAVE) applied to GBA1, the gene encoding lysosomal glucocerebrosidase. The team generated functional activity scores for more than 10,400 GBA1 variants, covering approximately 97 per cent of all possible single-amino-acid substitutions.

GBA1 is clinically important across two disease contexts: biallelic loss-of-function variants cause Gaucher disease, the most prevalent lysosomal storage disorder, while heterozygous GBA1 variants are among the most common genetic risk factors for Parkinson's disease. Despite this dual significance, systematic functional evidence for the majority of rare GBA1 variants has been lacking, leaving a large proportion of observed variants classified as variants of uncertain significance (VUS).

The authors report that their atlas recapitulated known structural and biochemical determinants of glucocerebrosidase activity and showed strong concordance with expert-curated pathogenicity classifications where those exist. The dataset is described as a harmonised functional reference framework intended to support variant interpretation across both disease contexts.

As a preprint, this work has not yet completed peer review. If the findings are confirmed, they could substantially reduce the VUS burden in GBA1 — a challenge familiar to genetic counsellors managing families with Gaucher disease or with a family history of Parkinson's risk. The scale of the dataset also makes it a resource of methodological interest for researchers developing or benchmarking variant effect predictors.

Plain-language version

For patients, families, and general readers. Educational only — not medical advice.

GBA1 is a gene that carries instructions for making an enzyme called glucocerebrosidase, which breaks down certain fatty substances inside cells. When both copies of GBA1 are severely faulty, a person develops Gaucher disease, a rare inherited condition. Having one mildly faulty copy also increases the risk of Parkinson's disease. Doctors often find small changes in this gene whose effects are unknown — these are called variants of uncertain significance, or VUS. Scientists have published a preprint — an early-stage research report awaiting independent expert review — describing an experiment that tested the effect of more than 10,000 different changes to the GBA1 gene on enzyme activity. The result is a large reference map that researchers hope will help interpret whether a given variant is harmful or harmless. This research does not change clinical care today, but it may help scientists and clinicians understand GBA1 variants better in the future. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary sourcePreprint bioRxiv · 2026-11-17
    A harmonized functional reference framework for GBA1

Tags

gba1 gaucher-disease parkinsons-disease mave variant-interpretation vus lysosomal-storage-disorder preprint
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List